

Laura B. Gottschalk -S
2021.09.20 15:13:08 -04'00'

From: Gottschalk, Laura
Sent: Monday, September 20, 2021 3:05 PM
To: Patel, Amit <Amitkumar.Patel@pfizer.com>
Cc: Devlin, Carmel M <Carmel.Devlin@pfizer.com>; Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; (b) (6) ; adrienne.stafford@pfizer.com; Smith, Michael (CBER) <Michael.Smith2@fda.hhs.gov>; Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>
Subject: STN 125742/9 - COVID-19 Vaccine, mRNA (COMIRNATY): Product Correspondence - CBER response to plan for reporting Biologic Product Deviation Reports

Dear Mr. Patel,

We refer you to your Product Correspondence submitted and received on September 15, 2021 to STN 125742/9 to request comments and advice for reporting of Biologic Product Deviation Reports to the EUA as well as to the BLA. We agree with your plan for reporting of Biological Product Deviation Reports to the BLA and including any affected EUA lots in those reports, as described in your STN 125742/9 submission.

Please acknowledge receipt of this communication and let me know if you have any questions.

Best regards,
Laura

Laura Gottschalk, PhD

Regulatory Project Manager/Primary Reviewer

Center for Biologics Evaluation and Research
Office of Vaccines Research and Review
U.S. Food and Drug Administration
Tel: 301-796-0798
laura.gottschalk@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.